About AKESO Company

Kangfang Biotechnology (Cayman) Co., Ltd. is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs that are affordable to patients around the world. Since its establishment, the company has established an end-to-end comprehensive drug development platform (ACE platform), covering fully integrated drug discovery and development functions, including target verification, antibody drug discovery and development, CMC production process development, and production that meets GMP standards. Our company has also successfully developed bispecific antibody drug development technology (TETRABODY technology), which helps us overcome the three CMC problems encountered in the development and production of bispecific antibodies, including low levels of expression, process development barriers, and antibody stability and pharmacogenicity. The company currently has more than 30 innovative projects under development, covering the fields of oncology, autoimmunity and metabolic diseases. Nineteen are in clinical trials (including 3 commercialized products and 4 externally authorized products), of which 6 are potentially first-in-class (first-in-class) or best-in-class (best-in-class) bispecific antibodies. The company hopes to become the world's leading biopharmaceutical company through efficient and innovative research and development to develop new drugs with the first of its kind or the best treatment in its class.